BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15637681)

  • 21. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts.
    Faquin WC; Cibas ES; Renshaw AA
    Cancer; 2005 Apr; 105(2):71-9. PubMed ID: 15662703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
    Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
    Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma.
    Choi CH; Kim TJ; Kim WY; Ahn GH; Lee JW; Kim BG; Lee JH; Bae DS
    Gynecol Oncol; 2007 Jun; 105(3):762-8. PubMed ID: 17383715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.
    Stewart CJ; Brennan BA; Crook ML; Russell P
    Histopathology; 2007 Sep; 51(3):313-21. PubMed ID: 17727474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
    Veras E; Deavers MT; Silva EG; Malpica A
    Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
    Liu JF; Hirsch MS; Lee H; Matulonis UA
    Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
    Vereczkey I; Tóth E; Orosz Z
    Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla.
    Stanwell P; Russell P; Carter J; Pather S; Heintze S; Mountford C
    Invest Radiol; 2008 Oct; 43(10):745-51. PubMed ID: 18791417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRI appearances of borderline ovarian tumours.
    Bent CL; Sahdev A; Rockall AG; Singh N; Sohaib SA; Reznek RH
    Clin Radiol; 2009 Apr; 64(4):430-8. PubMed ID: 19264189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type.
    Silva EG; Young RH
    Am J Surg Pathol; 2007 Aug; 31(8):1203-8. PubMed ID: 17667544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
    Roger N; Zafrani Y; Uzan C; Gouy S; Rey A; Pautier P; Lhommé C; Duvillard P; Castaigne D; Morice P
    Ann Surg Oncol; 2008 Jan; 15(1):333-8. PubMed ID: 17943386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
    Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.